| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
University of South Florida, Tampa, Florida 33612
Many advances have been made in the last few years concerning our understanding of the receptors and ligands composing the cannabinoid system. Likewise, the science surrounding cytokine biology has advanced enabling us to measure these proteins more precisely as well as understand and interpret the meaning of changes in their levels. Scientists wishing to study the health consequences of smoking marijuana as well as understand the possible role of endogenous cannabimimetic ligands in immune regulation have continued to study the influence of these substances on the regulation and development of the cytokine network. Research has shown that two major cannabinoid receptor subtypes exist and that subtype 1 (CB1) is expressed primarily in the brain whereas subtype 2 (CB2) is expressed primarily in the periphery. A variety of ligands for these receptors based on the cannabinoid structure have been synthesized and studied as well as low affinity compounds, noncannabinoid ligands, and endogenous ligands derived from fatty acid eicosanoids. Highly selective receptor antagonists have also been introduced and studied. Synthetic, low affinity ligands such as (+)-HU-211 and DMH-11C have been shown to cause anti-inflammatory effects possibly through inhibiting the production and action of TNF-
and other acute phase cytokines. In addition, suppression of TNF and other cytokines such as GM-CSF, IL-6, IFN
, and IL-12 has also been seen following exposure to high affinity and psychoactive ligands such as marijuana and THC. However, some of these ligands have also been shown to increase rather than decrease interleukins such as IL-1, IL-4, IL-10, and IL-6, cytokines such as TNF-, and chemokines such as IL-8, MIP-1, and RANTES. The endogenous ligand, anandamide, has been shown in culture to either suppress the proliferation response to prolactin or enhance the response to cytokines such as IL-3 and IL-6. This eicosanoid has also been shown to increase the production of interleukins and other cytokines. Cannabinoid receptors have been shown to be involved in some but not all of these effects. It is clear that psychoactive and nonpsychoactive compounds have demonstrated effects in vivo and in vitro on the production and function of a variety of cytokines. Depending upon the model system, these effects are often conflicting, and the involvement of cannabinoid receptors is unclear. However, enough evidence exists to suggest that the cannabinoid system significantly impacts the functioning of the cytokine network, and this association may provide clues to the mechanisms of certain immune diseases and form the basis for new immunotherapies.
This article has been cited by other articles:
|
|
 |
|
  F. Cianchi, L. Papucci, N. Schiavone, M. Lulli, L. Magnelli, M. C. Vinci, L. Messerini, C. Manera, E. Ronconi, P. Romagnani, et al. Cannabinoid Receptor Activation Induces Apoptosis through Tumor Necrosis Factor {alpha}-Mediated Ceramide De novo Synthesis in Colon Cancer Cells Clin. Cancer Res., December 1, 2008; 14(23): 7691 - 7700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bossola, F. Pacelli, A. Tortorelli, and G. B. Doglietto Cancer Cachexia: It's Time for More Clinical Trials Ann. Surg. Oncol., February 1, 2007; 14(2): 276 - 285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V Di Marzo and A A Izzo Endocannabinoid overactivity and intestinal inflammation. Gut, October 1, 2006; 55(10): 1373 - 1376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Roosterman, T. Goerge, S. W. Schneider, N. W. Bunnett, and M. Steinhoff Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. Physiol Rev, October 1, 2006; 86(4): 1309 - 1379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pacher, S. Batkai, and G. Kunos The Endocannabinoid System as an Emerging Target of Pharmacotherapy Pharmacol. Rev., September 1, 2006; 58(3): 389 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. K. Rao and N. E. Kaminski Cannabinoid-Mediated Elevation of Intracellular Calcium: A Structure-Activity Relationship J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 820 - 829. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kaczocha, A. Hermann, S. T. Glaser, I. N. Bojesen, and D. G. Deutsch Anandamide Uptake Is Consistent with Rate-limited Diffusion and Is Regulated by the Degree of Its Hydrolysis by Fatty Acid Amide Hydrolase J. Biol. Chem., April 7, 2006; 281(14): 9066 - 9075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. K. Rao and N. E. Kaminski Induction of intracellular calcium elevation by {Delta}9-tetrahydrocannabinol in T cells involves TRPC1 channels J. Leukoc. Biol., January 1, 2006; 79(1): 202 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Sipe, N. Arbour, A. Gerber, and E. Beutler Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: possible risk for autoimmune disorders J. Leukoc. Biol., July 1, 2005; 78(1): 231 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kadoi, H. Hinohara, F. Kunimoto, H. Kuwano, S. Saito, and F. Goto Effects of AM281, a cannabinoid antagonist, on systemic haemodynamics, internal carotid artery blood flow and mortality in septic shock in rats Br. J. Anaesth., May 1, 2005; 94(5): 563 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. McKallip, M. Nagarkatti, and P. S. Nagarkatti {Delta}-9-Tetrahydrocannabinol Enhances Breast Cancer Growth and Metastasis by Suppression of the Antitumor Immune Response J. Immunol., March 15, 2005; 174(6): 3281 - 3289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Newton, T. Lu, S. J. Nazian, I. Perkins, H. Friedman, and T. W. Klein The THC-induced suppression of Th1 polarization in response to Legionella pneumophila infection is not mediated by increases in corticosterone and PGE2 J. Leukoc. Biol., October 1, 2004; 76(4): 854 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. K. Rao, W. Zhang, and N. E. Kaminski Cannabinoid receptor-mediated regulation of intracellular calcium by {Delta}9-tetrahydrocannabinol in resting T cells J. Leukoc. Biol., May 1, 2004; 75(5): 884 - 892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Di Filippo, F. Rossi, S. Rossi, and M. D'Amico Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN J. Leukoc. Biol., March 1, 2004; 75(3): 453 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. W. Klein, C. Newton, K. Larsen, L. Lu, I. Perkins, L. Nong, and H. Friedman The cannabinoid system and immune modulation J. Leukoc. Biol., October 1, 2003; 74(4): 486 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Molina-Holgado, E. Pinteaux, J. D. Moore, E. Molina-Holgado, C. Guaza, R. M. Gibson, and N. J. Rothwell Endogenous Interleukin-1 Receptor Antagonist Mediates Anti-Inflammatory and Neuroprotective Actions of Cannabinoids in Neurons and Glia J. Neurosci., July 23, 2003; 23(16): 6470 - 6474. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Friedman, C. Newton, and T. W. Klein Microbial Infections, Immunomodulation, and Drugs of Abuse Clin. Microbiol. Rev., April 1, 2003; 16(2): 209 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Arevalo-Martin, J. M. Vela, E. Molina-Holgado, J. Borrell, and C. Guaza Therapeutic Action of Cannabinoids in a Murine Model of Multiple Sclerosis J. Neurosci., April 1, 2003; 23(7): 2511 - 2516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Molina-Holgado, J. M. Vela, A. Arevalo-Martin, G. Almazan, F. Molina-Holgado, J. Borrell, and C. Guaza Cannabinoids Promote Oligodendrocyte Progenitor Survival: Involvement of Cannabinoid Receptors and Phosphatidylinositol-3 Kinase/Akt Signaling J. Neurosci., November 15, 2002; 22(22): 9742 - 9753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. McKallip, C. Lombard, B. R. Martin, M. Nagarkatti, and P. S. Nagarkatti Delta 9-Tetrahydrocannabinol-Induced Apoptosis in the Thymus and Spleen as a Mechanism of Immunosuppression in Vitro and in Vivo J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 451 - 465. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. McKallip, C. Lombard, M. Fisher, B. R. Martin, S. Ryu, S. Grant, P. S. Nagarkatti, and M. Nagarkatti Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease Blood, June 28, 2002; 100(2): 627 - 634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. T. Carter and B. S. Rosen Marijuana in the management of amyotrophic lateral sclerosis American Journal of Hospice and Palliative Medicine, July 1, 2001; 18(4): 264 - 270. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
